ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SIMPLE
- Sponsors AbbVie
- 27 Oct 2017 Interim results of 24 week study period assessing safety and efficacy presented at the 16th European AIDS Conference.
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.